Alterity Therapeutics presents new data on ATH434 showing potential for treating neurodegenerative diseases.

From GlobeNewswire.: 2024-10-11 07:35:00

Alterity Therapeutics presented new data on ATH434 at the Society for Neuroscience 2024, showing the compound’s potential in treating neurodegenerative diseases. The study, led by Dr. Daniel J. Kosman, highlighted ATH434’s antioxidant properties and benefits in cellular energy usage, making it a promising candidate for diseases like Parkinson’s.

The study by Dr. Danielle Bailey demonstrated ATH434’s efficacy in protecting against lipid peroxidation in neuronal cells under oxidative stress. ATH434’s ability to enhance energy production in mitochondria and serve as a direct antioxidant can protect vulnerable mitochondria in neurodegenerative diseases, further emphasizing its therapeutic potential.

ATH434, Alterity’s lead candidate, is designed to inhibit the aggregation of pathological proteins involved in neurodegeneration. Preclinical studies have shown its ability to reduce α-synuclein pathology and restore normal iron balance in the brain. With ongoing Phase 2 clinical trials in MSA patients, ATH434 holds promise in treating Parkinsonian disorders.

Alterity Therapeutics is focused on developing innovative therapies for neurodegenerative diseases. Their lead asset, ATH434, is currently being evaluated in clinical trials for Multiple System Atrophy. The company’s drug discovery platform aims to generate compounds that target the underlying pathology of neurological disorders, offering hope for patients with debilitating conditions.



Read more at GlobeNewswire.: Alterity Therapeutics Announces Presentation of New Data